论文部分内容阅读
The breakthrough of immune checkpoint inhibitor(ICI)therapy has created extensive opportunities for cancer immunotherapy.Especially,the block of programmed death-1/programmed death ligand 1(PD-L1)axis using ICIs has become a new therapeutic strategy to tr